|
Hi Irene. I'm not sure if this is the one that tammy Faye talked about, but there is an orally administered angiogenesis inhibitor being used in Phase III clinical trials, that is made by Schering. It is known as PTK787/ZK 222584.
PTK787/ZK 222584 is a novel oral angiogenesis inhibitor that potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
|
Threaded Mode